The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR)

被引:2
|
作者
Inchakalody, Varghese P. [1 ,2 ]
Hydrose, Shereena P. [1 ,2 ]
Krishnankutty, Roopesh [3 ]
Merhi, Maysaloun [1 ,2 ]
Therachiyil, Lubna [3 ,12 ]
Nair, Varun Sasidharan [7 ]
Elashi, Asma A. [8 ]
Khan, Abdul Q. [3 ]
Taleb, Sara [6 ]
Raza, Afsheen [1 ,2 ]
Yoosuf, Zeenath Safira K. M. [2 ,8 ]
Fernandes, Queenie [2 ,9 ]
Al-Zaidan, Lobna [1 ,2 ]
Mestiri, Sarra [1 ,2 ]
Taib, Nassiba [1 ,2 ]
Bedhiafi, Takwa [1 ,2 ]
Moustafa, Dina [1 ,2 ]
Assami, Laila [1 ,2 ]
Maalej, Karama Makni [1 ,2 ]
Elkord, Eyad [10 ,11 ]
Uddin, Shahab [4 ,5 ]
Al Homsi, Ussama [1 ,2 ]
Dermime, Said [1 ,2 ]
机构
[1] Hamad Med Corp, Natl Ctr Canc Care & Res, Doha, Qatar
[2] Hamad Med Corp, Interim Translat Res Inst, Translat Canc Res Facil, Doha, Qatar
[3] Hamad Med Corp, Translat Res Inst, Acad Hlth Syst, Doha, Qatar
[4] Acad Hlth Syst, Translat Res Inst, Doha, Qatar
[5] Acad Hlth Syst, Dermatol Inst, Doha, Qatar
[6] Hamad Bin Khalifa Univ, Genom & Precis Med, Doha, Qatar
[7] Helmholtz Ctr Infect Res, Dept Expt Immunol, Braunschweig, Germany
[8] Hamad Bin Khalifa Univ, Coll Hlth & Life Sci, Doha, Qatar
[9] Qatar Univ, Coll Med, Doha, Qatar
[10] Univ Nizwa, Nat & Med Sci Res Ctr, Translat Canc Res Facil, Nizwa, Oman
[11] Univ Salford, Sch Sci Engn & Environm, Biomed Res Ctr, Manchester, Lancs, England
[12] Qatar Univ, Coll Pharm, Doha, Qatar
关键词
Non small lung cancer; 5; Aza-CdR; Epigenetic regulation; NY-ESO-1; Apoptosis; Intrinsic and extrinsic apoptotic pathway; EXPRESSION; PROTEINS; 5-AZA-2'-DEOXYCYTIDINE; ENRICHMENT; GROWTH;
D O I
10.1016/j.ejphar.2023.175612
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dysregulated epigenetic modifications are common in lung cancer but have been reversed using demethylating agent like 5-Aza-CdR. 5-Aza-CdR induces/upregulates the NY-ESO-1 antigen in lung cancer. Therefore, we investigated the molecular mechanisms accompanied with the epigenetic regulation of NY-ESO-1 in 5-Aza-CdR-treated NCI-H1975 cell line. We showed significant induction of the NY-ESO-1 protein (**p < 0.0097) using Cellular ELISA. Bisulfite-sequencing demonstrated 45.6% demethylation efficiency at the NY-ESO-1 gene pro-moter region and RT-qPCR analysis confirmed the significant induction of NY-ESO-1 at mRNA level (128-fold increase, *p < 0.050). We then investigated the mechanism by which 5-Aza-CdR inhibits cell proliferation in the NCI-H1975 cell line. Upregulation of the death receptors TRAIL (2.04-fold *p < 0.011) and FAS (2.1-fold *p < 0.011) indicate activation of the extrinsic apoptotic pathway. The upregulation of Voltage-dependent anion-selective channel protein 1 (1.9-fold), Major vault protein (1.8-fold), Bax (1.16-fold), and Cytochrome C (1.39-fold) indicate the activation of the intrinsic pathway. We also observed the differential expression of protein Complement C3 (3.3-fold), Destrin (-5.1-fold), Vimentin (-1.7-fold), Peroxiredoxin 4 (-1.6-fold), Fascin (- 1.8-fold), Heme oxygenase-2 (-0.67-fold**p < 0.0055), Hsp27 (-0.57-fold**p < 0.004), and Hsp70 (-0.39-fold **p < 0.001), indicating reduced cell growth, cell migration, and metastasis. The upregulation of 40S ribosomal protein S9 (3-fold), 40S ribosomal protein S15 (4.2-fold), 40S ribosomal protein S18 (2.5-fold), and 60S ribo-somal protein L22 (4.4-fold) implied the induction of translation machinery. These results reiterate the decisive role of 5-Aza-CdR in lung cancer treatment since it induces the epigenetic regulation of NY-ESO-1 antigen, in-hibits cell proliferation, increases apoptosis, and decreases invasiveness.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] ASSOCIATION OF NEW YORK-ESOPHAGEAL ANTIGEN-1 (NY-ESO-1) PROMOTER METHYLATION AND SURVIVAL IN STAGE III NON-SMALL CELL LUNG CANCER
    Liew, Mun Sem
    Chueh, Anderly C.
    Walkiewicz, Marzena
    Cebon, Jonathan
    Mitchell, Paul
    Mariadason, John
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S793 - S793
  • [12] Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer
    Chueh, Anderly C.
    Liew, Mun-Sem
    Russell, Prudence A.
    Walkiewicz, Marzena
    Jayachandran, Aparna
    Starmans, Maud H. W.
    Boutros, Paul C.
    Wright, Gavin
    Barnett, Stephen A.
    Mariadason, John M.
    John, Thomas
    ONCOTARGET, 2017, 8 (43) : 74036 - 74048
  • [13] ANALYSIS OF NY-ESO-1 EXPRESSION IN SPECIMENS FROM A PHASE I/II NY-ESO-1 T-CELL THERAPY CLINICAL TRIAL IN NON-SMALL CELL LUNG CANCER AND FROM EXPLORATORY STUDIES IN MULTIPLE TUMOR TYPES
    Barnes, Bryan
    Shan, Ming
    Blouch, Kristin
    Altan, Mehmet
    Kim, Jaegil
    Ramos-Hernandez, Natalia
    Corigliano, Ellie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A482 - A482
  • [14] Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report
    Xia, Yan
    Tian, Xiaopeng
    Wang, Juntao
    Qiao, Dongjuan
    Liu, Xianhao
    Xiao, Liang
    Liang, Wenli
    Ban, Dongcheng
    Chu, Junjun
    Yu, Jiaming
    Wang, Rongfu
    Tian, Geng
    Wang, Mingjun
    ONCOLOGY LETTERS, 2018, 16 (06) : 6998 - 7007
  • [15] Serum antibody against NY-ESO-1 and XAGE1 predicts clinical responses to anti-PD-1 therapy in non-small cell lung cancer
    Kurose, Koji
    Ohue, Yoshihiro
    Karasaki, Takahiro
    Futami, Junichiro
    Irei, Isao
    Masuda, Takeshi
    Fukuda, Masaaki
    Kinoshita, Akitoshi
    Matsushita, Hirokazu
    Shimizu, Katsuhiko
    Yamaguchi, Hiroyuki
    Fukuda, Minoru
    Kakimi, Kazuhiro
    Oka, Mikio
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [16] Immunohystochemical Expression of Cancer/Testis Antigens (MAGE-A3/4, NY-ESO-1) in Non-Small Cell Lung Cancer: The Relationship with Clinical-Pathological Features
    Grah, Josip
    Samija, Mirko
    Juretic, Antonio
    Garcevic, Bozena
    Sobat, Hrvoje
    COLLEGIUM ANTROPOLOGICUM, 2008, 32 (03) : 731 - 736
  • [17] Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Jung, Eun Hee
    Jang, Hee Ryeong
    Kim, Se Hyun
    Suh, Koung Jin
    Kim, Yu Jung
    Lee, Ju-Hyun
    Chung, Jin-Haeng
    Kim, Miso
    Keam, Bhumsuk
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    Lee, Jong Seok
    THORACIC CANCER, 2021, 12 (05) : 619 - 630
  • [18] Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression
    Hou, Zhenbo
    Liang, Xiao
    Wang, Xinmei
    Zhou, Ziqiang
    Shi, Guilan
    ONCOLOGY LETTERS, 2020, 19 (06) : 3982 - 3992
  • [19] Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance
    Yoshida, N
    Abe, H
    Ohkuri, T
    Wakita, D
    Sato, M
    Noguchi, D
    Miyamoto, M
    Morikawa, T
    Kondo, S
    Ikeda, H
    Nishimura, T
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2006, 28 (05) : 1089 - 1098
  • [20] Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer
    Sakaeda, Kanako
    Kurose, Koji
    Matsumura, Yuki
    Muto, Satoshi
    Fukuda, Minoru
    Sugasaki, Nanae
    Fukuda, Masaaki
    Takemoto, Shinnosuke
    Taniguchi, Hirokazu
    Masuda, Takeshi
    Shimizu, Katsuhiko
    Kataoka, Yuki
    Irino, Yasuhiro
    Sakai, Yumiko
    Atarashi, Yusuke
    Yanagida, Masatoshi
    Hattori, Noboru
    Mukae, Hiroshi
    Nakata, Masao
    Kanda, Eiichiro
    Oga, Toru
    Suzuki, Hiroyuki
    Oka, Mikio
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 40